Dr. Suzanne Lentzsch is an Associate Professor of Clinical Medicine and the Director of the Multiple Myeloma and Amyloidosis Program at the College of Physicians and Surgeons of Columbia University and at New York Presbyterian Hospital in New York. She received her degrees from the Humboldt University/Charité Berlin, Germany, and completed her residency and fellowship at Humboldt University. Dr. Lentzsch completed a research fellowship, studying the mechanism of action of thalidomide and its derivatives in multiple myeloma, in the Jerome Lipper Multiple Myeloma Center under the mentorship of Dr. Kenneth Anderson at the Dana-Farber Cancer Institute, Boston, Massachusetts.
Dr. Lentzsch was recruited in August 2004 to the University of Pittsburgh and University of Pittsburgh Cancer Institute (UPCI), PA, USA, and served as Clinical Director of the Multiple Myeloma Program at UPCI before accepting the position as Director of the Multiple Myeloma and Amyloidosis Program at Columbia University Medical Center. She cares primarily for patients with plasma cell dyscrasia including MGUS, multiple myeloma, amyloidosis, POEMS and Waldenstrom's macroglobulinemia.
Dr. Lentzsch is an internationally recognized expert in the field of multiple myeloma and amyloidosis. She serves as a SWOG Myeloma Committee Member, SWOG Study Coordinator and International Myeloma Foundation "Black Swan Research Initiative" committee member. She is a member of the standing advisory board for the evaluation of secondary primary malignancies associated with IMiDs.